In the News
- In the News
Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company.
- In the News
Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
- In the News
New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle.
- In the News
The investment community is chasing a longer, healthier life like the rest of us.
- In the News
What makes longevity one of the greatest investment opportunities in human history?
- In the News
There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health
- In the News
The leaders of the Buck Institute for Research on Aging want you to know that they’re not going to make you immortal.
- In the News
Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
- In the News
Greg goes deep on Juvenescence, longevity biotech and his personal story.
- In the News
Healthspan and longevity research has exploded in the past decade, and as scientists learn more about the biology of aging
- In the News
Everyone ages — it’s one of the indisputable facts of life. From the moment we are born, each one of us starts a linear process of growth and maturation
- In the News
The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.